Cryptococcosis Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Cryptococcosis Therapeutics Market is Segmented by Treatment (Amphotericin B, Flucytosine, Fluconazole, Others) and Geography.

Cryptococcosis Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Cryptococcosis Therapeutics Market Size

Cryptococcosis Therapeutics Market
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 4.70 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Cryptococcosis Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Cryptococcosis Therapeutics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Cryptococcosis Therapeutics Market Analysis

The Cryptococcosis Therapeutics Market is expected to register a CAGR of 4.7% during the forecast period.

Cryptococcosis is a fungal infection which is caused by Cryptococcus neoformans and Cryptococcus gattii which primarily affects the central nervous system and the lungs. People with diseases such as AIDS, hodgkin lymphoma, other lymphomas, sarcoidosis, and solid organ transplantation with weakened immune systems are generally more susceptible to this type of infection. 

Cryptococcosis is usually acquired by inhalation of dust containing yeast cells which typically affects the lungs. Cryptococcosis symptoms include fever, malaise, cough, hemoptysis (bloody or blood-tinged sputum), headache, vision changes (blurry or double vision, photophobia) etc. Cryptococcosis diagnosis is clinical and microscopic, which is confirmed by culture or fixed-tissue staining. 

According to the United Nations Program on HIV/AIDS and the World Health Organization, globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 deaths approximately. According to the Centers for Disease Control and Prevention and WHO, it is estimated that globally every year 220,000 cases of cryptococcal meningitis occur among people with HIV/AIDS, resulting in nearly 181,000 deaths. Therefore with the growing prevalence of cryptococcosis and availability of advance treatment are the key factors that drives the growth of cryptococcosis diseases market. However, adverse effects associated with the use of medication is likely to restrain the market growth in the forecast period.

Cryptococcosis Therapeutics Industry Overview

The Cryptococcosis Therapeutics Market is moderately consolidated and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some companies are adopting numerous strategies including acquisitions and collaborations to sustain market competition.

Cryptococcosis Therapeutics Market Leaders

  1. Bristol-Myers Squibb Company

  2. Pfizer Inc

  3. Astellas Pharma Inc.

  4. Sigmapharm Laboratories LLC

  5. Glenmark Pharmaceuticals

  6. *Disclaimer: Major Players sorted in no particular order
Brachytherapy Devices Market -2
Need More Details on Market Players and Competiters?
Download PDF

Cryptococcosis Therapeutics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Fatal Fungal Disease
    • 4.2.2 Favourable Reimbursement Policies
    • 4.2.3 New and Advanced Treatment Opportunities
  • 4.3 Market Restraints
    • 4.3.1 Adverse Effects of the Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 By Treatment
    • 5.1.1 Amphotericin B
    • 5.1.2 Flucytosine
    • 5.1.3 Fluconazole
    • 5.1.4 Others
  • 5.2 Geography
    • 5.2.1 North America
    • 5.2.1.1 United States
    • 5.2.1.2 Canada
    • 5.2.1.3 Mexico
    • 5.2.2 Europe
    • 5.2.2.1 Germany
    • 5.2.2.2 United Kingdom
    • 5.2.2.3 France
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
    • 5.2.3.1 China
    • 5.2.3.2 Japan
    • 5.2.3.3 India
    • 5.2.3.4 Australia
    • 5.2.3.5 South Korea
    • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
    • 5.2.4.1 GCC
    • 5.2.4.2 South Africa
    • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
    • 5.2.5.1 Brazil
    • 5.2.5.2 Argentina
    • 5.2.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Astellas Pharma Inc
    • 6.1.2 Bristol-Myers Squibb Company
    • 6.1.3 Glenmark Pharmaceuticals
    • 6.1.4 Janssen Biotech Inc. (Johnson & Johnson)
    • 6.1.5 Novartis AG
    • 6.1.6 Pfizer Inc.
    • 6.1.7 Sigmapharm Laboratories LLC
    • 6.1.8 Valeant Pharmaceuticals Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Cryptococcosis Therapeutics Industry Segmentation

As per the scope of the report, cryptococcosis is a fungal infection which is caused by Cryptococcus neoformans and Cryptococcus gattii which primarily affects the central nervous system and the lungs. Cryptococcosis infect humans and animals, usually by inhalation of the fungus, which results in lung infection that may spread to the brain, causing meningoencephalitis.

By Treatment Amphotericin B
Flucytosine
Fluconazole
Others
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Cryptococcosis Therapeutics Market Research FAQs

What is the current Cryptococcosis Therapeutics Market size?

The Cryptococcosis Therapeutics Market is projected to register a CAGR of 4.7% during the forecast period (2025-2030)

Who are the key players in Cryptococcosis Therapeutics Market?

Bristol-Myers Squibb Company, Pfizer Inc, Astellas Pharma Inc., Sigmapharm Laboratories LLC and Glenmark Pharmaceuticals are the major companies operating in the Cryptococcosis Therapeutics Market.

Which is the fastest growing region in Cryptococcosis Therapeutics Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Cryptococcosis Therapeutics Market?

In 2025, the North America accounts for the largest market share in Cryptococcosis Therapeutics Market.

What years does this Cryptococcosis Therapeutics Market cover?

The report covers the Cryptococcosis Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Cryptococcosis Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Cryptococcosis Therapeutics Industry Report

Statistics for the 2025 Cryptococcosis Therapeutics market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. Cryptococcosis Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Cryptococcosis Therapeutics Report Snapshots